Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?   

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision?  What about whether this is in the first-line vs. 2nd/3rd-line setting? 

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Virginia Cancer Institute
Do you employ this strategy regardless of the pati...
Medical Oncologist at University of North Carolina School of Medicine
In terms of how I consider intracarnial vs. system...
Sign in or Register to read more